Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Pediatr. Sep 9, 2026; 15(3): 118236
Published online Sep 9, 2026. doi: 10.5409/wjcp.118236
Patient satisfaction and performance of the A8+ TouchCare Nano in children and adolescents with type 1 diabetes mellitus
Konstantina Kosta, Maria G Grammatikopoulou, Ilektra Toulia, Penelope Smyrnaki, Eleni G Paschalidou, Anastasios Vamvakis, Antonios Bogiatzoglou, Christos Tzimos, Kyriaki Tsiroukidou
Konstantina Kosta, Ilektra Toulia, Eleni G Paschalidou, Antonios Bogiatzoglou, Kyriaki Tsiroukidou, Pediatric Endocrinology Unit, 3rd Department of Pediatrics, Hippokration General Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki GR-54124, Kentrikí Makedonía, Greece
Maria G Grammatikopoulou, Immunonutrition and Clinical Nutrition Unit, Department of Rheumatology and Clinical Immunology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis Campus, Larissa GR-41223, Greece
Penelope Smyrnaki, Pediatric Endocrinology Clinic, Heraclion GR-71303, Greece
Anastasios Vamvakis, Department of Nutritional Sciences and Dietetics, Hellenic Mediterranean University, Siteia GR-72300, Kríti, Greece
Christos Tzimos, Northern Greece Statistics Directorate, Hellenic Statistical Authority, Thessaloniki GR-54646, Kentrikí Makedonía, Greece
Co-first authors: Konstantina Kosta and Maria G Grammatikopoulou.
Author contributions: Kosta K and Grammatikopoulou MG contributed equally to this article, they are the co-first authors of this manuscript; Kosta K, Toulia I, and Smyrnaki P contributed to data collection; Grammatikopoulou MG contributed to the methodology, writing; Grammatikopoulou MG, Toulia I, and Smyrnaki P contributed to reviewing and editing the manuscript; Paschalidou EG, Vamvakis A, and Bogiatzoglou A collected the data and created the databases used in the analyses; Tzimos C contributed to the statistical analyses; Tsiroukidou K contributed to the conceptualization, methodology, reviewing, editing and supervising the work; and all authors contributed to the interpretation of the study and approved the final version to be published.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Hippokration General Hospital, approval No. 313/24-04-2025.
Informed consent statement: Parents and guardians of all participants provided consent to participation in the study’s protocol.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: All data are available upon request to the senior author.
Corresponding author: Maria G Grammatikopoulou, PhD, Assistant Professor, Immunonutrition and Clinical Nutrition Unit, Department of Rheumatology and Clinical Immunology, Uni
versity General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis Campus, Argonafton and Filellinon Street, Larissa GR-41223, Greece.
mgrammat@uth.gr
Received: December 28, 2025
Revised: February 22, 2026
Accepted: April 23, 2026
Published online: September 9, 2026
Processing time: 214 Days and 22 Hours
BACKGROUND
The role of automated insulin delivery systems in type 1 diabetes mellitus (T1DM) is constantly expanding, merging continuous glucose monitoring readings with a control algorithm and a continuous subcutaneous insulin infusion device, i.e. insulin pump.
AIM
To evaluate the effectiveness of a new, open and closed-loop insulin delivery system in children and adolescents with T1DM.
METHODS
Children and adolescents with T1DM (n = 28) were recruited from two pediatric endocrinology clinics situated in Thessaloniki and Crete (Greece), during the year 2025. The Medtrum A8+ TouchCare Nano system was used on all patients and comparison of glycemic control and treatment satisfaction were evaluated before and after the introduction of the new system.
RESULTS
The results showed increased patient satisfaction with the continuous subcutaneous insulin infusion, in particular when the closed-loop system was integrated. Participants were satisfied with most of the system’s features, including the predictive low glucose suspend feature, aiming in preventing hypoglycemic episodes and the Auto Meal Handling feature, adjusting the carbohydrate content of each meal without necessitating carbohydrate counting. Time in range, glycosylated haemoglobin levels glucose management indicator, time above range, very high glucose levels, time in tight range and average blood glucose levels were improved after the introduction of the new system. The results remained similar even when closed/open loop systems were evaluated, or when the sample was divided in pre-pubertal/pubescent participants. No adverse events were recorded.
CONCLUSION
The results indicate the that Medtrum A8+ TouchCare Nano system is safe and effective in maintaining and improving glycemic control in children and adolescents with T1DM. More research on pediatric patients is required to further verify these results.
Core Tip: We showed that the Medtrum A8+ TouchCare Nano system is safe and efficient to use among pediatric and adolescent patients with type 1 diabetes mellitus. Furthermore, high treatment satisfaction was recorded among participants after switching to the Medtrum system. Collectively, the present findings add to the available data on the performance and efficacy of the system, paving the way for a more evidence-based prescription of the TouchCare Nano in youngsters with type 1 diabetes mellitus.
